

REFERENCES

- Abuelo, J.; Gary, Pavel Vancura and Bruce, S. Chang, (1989):**
Renal pathophysiology the essentials. Chronic Renal Failure
Williams and Wilkins, PP. 217-236.
- Adamson, J.; Longo, D. (2001):**
Anaemia and Polycythemia. In: Braunwald E., Fauci, AS,
Isselbacher, K, Kasper DL, Hauser SL, Longo DL, Jameson
JL (eds). Harrison's Principles of Internal Medicine, 15th ed.
MC Graw Hill, New York, 1551-1561.
- Agens, Fogo and Valentina Kon (1999):**
Pathophysiology of progressive renal disease, from pediatric
nephrology, 4th Ed: T. Martin, Ellis D., Harmon P: 1183-85.
- Akimoto, T.; Kusano, E.; Fujita, N.; Okada, K.; Saito, O.; Ono, S.;
Ando, Y.; Homma, S.; Saito, T.; Asano, Y. (2001):**
Erythropoietin modulates angiotensin II- or noradrenaline
induced Ca²⁺ mobilization in cultured rat vascular smooth-
muscle cells.
Nephrol. Dial. Transplant., 16(3): 491-499.
- Allen, D.A.; Breen, C.; Yaqoob, M.M.; Macdougall, I.C. (1999):**
Inhibition of CFU-E colony formation in uremic patients
with inflammatory disease: Role of INF-gamma and TNF-
alpha.
J. Invest. Med., 47: 204-211.
- Alfery, A.C. and Chan, L. (1992):**
Pathogenesis of CRF, in renal and electrolyte disorders, 4th
ed., Schrier RW, Brown and Company, Boston, P: 568.
- Altmann, P. (1993):**
Aluminium toxicity in dialysis patients: No evidence for a
threshold serum aluminium concentration.
Nephrol. Dial. Transplant., 8(Suppl. 1): 254-234.
- Andrews, N. (1999):**
Disorders of iron metabolism.
N. Engl. J. Med., 341: 1986-1995.

- Apajasale, M.; Rautomes, J. and Sintones, H. (1997):**
Health related quality of life after organ transplantation in children.
Ped. Transplant., P: B0-7.
- Barany, P. (2001):**
Inflammation, serum C-reactive protein, and erythropoietin resistance.
Nephrol. Dial. Transplant., 16: 224-227.
- Barany, P.; Divino Filho, J.C.; Bergstrom, J. (1997):**
High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients.
Am. J. Kidney Dis., 29: 565-568.
- Beguin, Y.; Loo, M.; R'Zik, S.; Sautois, B.; Lejeune, F.; Rorive, G.; Fillet, G. (1993):**
Early prediction of response to recombinant human erythropoietin in patients with anemia of renal failure by serum transferrin receptor and fibrinogen.
Blood, 82: 2010-2016.
- Bergrem, H.; Danielson, B.; Eckardt, K.; Kurtz, A.; Stridsberg, M. (1993):**
A case of anti erythropoietin antibodies following recombinant human erythropoietin treatment. In: Bauer C, Kock K, Sciqalla P eds. Erythropoietin: Molecular Physiology and Clinical Application. Marcel Dekker, New York, 265-275.
- Bergstrom, J. (2000):**
Inflammation, malnutrition, cardiovascular disease and mortality in end-stage renal disease.
Pol. Arch. Med. Wewn.; 104:641-643.
- Besarab, A.; Caro, J.; Jarrell, B.; Francos, G.; Erslev, A. (1987):**
A dynamics of erythropoietin following renal transplantation.
Kidney Int., 32: 526-536.
- Besarab, A.; Keiser, J.W.; Frinak, S. (1999):**
A study of parenteral iron regimens in hemodialysis patients.
Am. J. Kidney Dis., 34: 21-28.

- Bianchi, R.; Buyukakilli, B.; Brines, M.; Savino, C.; Cavaletti, G.; Oggioni, N.; Lauria, G.; Borgna, M.; Lombardi, R.; Cimen, B.; Comelekoglu, U.; Kanik, A.; Tataroglu, C.; Cerami, A.; Ghezzi, P. (2004):**
Erythropoietin both protects from and reverses experimental diabetic neuropathy.
PNAS, 101: 823-82.
- Bologa, R.M.; Levine, D.M.; Parker, T.S. et al. (1998):**
Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients.
Am. J. Kidney Dis.; 32:107-114.
- Bommer, J.; Gemsa, D.; Waldherr, R.; Kessler, J.; Ritz, E. (1984):**
Plastic filing from dialysis tubing induces prostanoïd release from macrophages.
Kidney Int., 26(3): 331-337.
- Bommer, J.; Titz, E.; Waldherr, R. (1981):**
Silicone induced splenomegaly: treatment of pancytopenia by splenectomy in a patient on haemodialysis.
N. Engl. J. Med., 305: 1077.
- Borawski, J.; Naumnik, B.; Pawlak, K.; Mysliwiec, M. (2001):**
Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: Associations with pre-dialysis blood pressure and the acute phase response.
Nephrol. Dial. Transplant., 16: 1442-1447.
- Borawski, J.; Rydzewski, A.; Mazerska, M.; Kalinowski, M.; Pawlak, K.; Mysliwiec, M. (1996):**
Inverse relationships between haemoglobin and ristocetin-induced platelet aggregation in haemodialysis patients under erythropoietin therapy.
Nephrol. Dial. Transplant., 11: 2444-2448.
- Borawski, J.; Pawlak, K.; Mysliwiec, M. (1999):**
Variables affecting hemoglobin level in hemodialysis patients (abstract).
Nephrol. Dial. Transplant., 14: A252.
- Borawski, J.; Pawlak, K.; Mysliwiec, M. (2000):**

Comparison of different assays for von Willebrand factor in hemodialysis patients.
Haemostasis, 30: 308-315.

Borawski, J.; Naumnik, B.; Pawlak, K.; Mysliwiec, M. (2001):
Soluble thrombomodulin is associated with viral hepatitis, blood pressure, and medications in haemodialysis patients.
Nephrol. Dial. Transplant., 16: 787-793.

Borawski, J.; Pawlak K, Mysliwiec M. (2002):
Inflammatory markers and platelet aggregation tests as predictors of hemoglobin and endogenous erythropoietin level in hemodialysis patients. Nephron; 91 : 671-681.

Born, G.V.R. (1962):
Aggregation of blood platelets by adenosine diphosphate and its reversal.
Nature, 194: 927-929.

Brancaccio, D.; Cozzolino, M.; Gallieni, M. (2004):
Hyper-parathyroidism and anaemia in uremic subjects: A combined therapeutic approach.
J. Am. Soc. Nephrol., 15: 521-524.

Brenner Barry, M.; Rector Floyd, C.Jr. (1996):
The Kidney, Hematological consequences of renal failure.
Volume II Fifth edition, P. 2170-2181.

Brenner, B.M. (1998):
Neurological complications of chronic renal failure. In: Kid. Int. P: 1520-36, W.S. Saunders, Philadelphia.

Bunn, F. (2002):
Drug-induced autoimmune red cell aplasia.
New Engl. J. Med., 346: 522-523.

Bunn, H. (2002):
Sugar in erythropoietin: clinical and forensic implications.
Blood, 99(5): 1503-1503.

Burstein, S.A. (1997):
Cytokines, platelet production and hemostasis.
Platelets, 8: 93-104.

- Burwen, D.; Olsen, S.; Bland, L.; Arduino, M.; Reid, M.; Jarvis, W. (1995):**
Epidemic Al toxication in haemodialysis patients traced to use of an aluminum pump.
Kidney Int., 48: 469-474.
- Cameron, J. (1999b):**
Chairman's workshop report. European best practice guidelines for the management of anaemia in patients with chronic renal failure.
Nephrol. Dial. Transplant., 14: 61-65.
- Canaud, B. and Carred, L. (1990):**
R-HuEPO in haemodialysis patients.
Am. J. Kid. Dis., 15: 165-175.
- Cannata, J.; Diaz Lopez, J. (1991):**
Insights into the complex aluminium and iron relationship.
Nephrol. Dial. Transplant., 6: 605-607.
- Carnot, P.; Deflandre, C. (1992):**
Sur Pactivite hemopoetique de serum au cour de la regeneration du sang. CR Acad Sci Paris 1906; 143: 384-386. Quoted from Jelkmann W. Erythropoietin: Structure, control of production, and function. Physiol. Rev., 72: 449-489.
- Casadeval, N.; Dupuy, E.; Molho-Sabatier, P.; Tobelem, G.; Varet, B.; Mayeux, P. (1996):**
Autoantibodies against erythropoietin in a patient with pure red-cell aplasia.
N. Engl. J. Med., 334(10): 630-633.
- Casadevall, N. (2002):**
Antibodies against rHu-EPO: native and recombinant.
Nephrol. Dial. Transplant., 17: 42-47.
- Casadevall, N.; Nataf, J.; Viron, B.; Kolta, A.; Kiladjian, J.; Martin-Dupont, P.; Michaud, P.; Papo, T.; Ugo, V.; Teyssandier, I.; Varet, B.; Mayeux, P. (2002):**
Pure Red-Cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.

N. Engl. J. Med., 346: 469-475.

Casadevall, N. (2003):

Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin.

Nephrol. Dial. Transplant., 18: VIII37-VIII41.

Castelli, G.; Famularo, A.; Semino, C.; Maria, A.; Ceci, A.; Cannella, G.; Melioli, G. (2000):

Detection of anti-erythropoietin antibodies in haemodialysis patients treated with recombinant human erythropoietin.

Pharmacological research, 41(3): 313-318.

Chantler, C. and Holliday, M. (1987):

Progressive loss of renal function. In Pediatric nephrology, 2nd edition, Holliday MA, Barratt TM, Vernier RL (eds). Williams and Wilkins, Baltimore, PP. 773-798.

Charache, S.; Terrin, M.; Moore, R.; Dover, G.; Barton, F.; Eckert, S.; McMahon, R.; Bonds, D. (1995):

Effect of hydroxyurea on the frequency of painful crises in sickle cell anaemia.

N. Engl. J. Med., 332: 1317-1322.

Chenseny, R.W. and Avioli, L.V. (1992):

Childhood renal osteodystrophy. In: Ped. Kid. Dis., 2nd ed., Eds, Edelman CM, Brenstien J and Meadow, Brown and Company, Bosron; P: 647-74.

Chng, W.; Tan, L.; Liu, T. (2003):

Cyclosporine treatment for patients with CRF who developed pure red blood cell aplasia following EPO therapy.

Am. J. Kidney Dis., 41(3): 692-5.

Cines, D.B.; Pollak, E.S.; Buck, C.A.; Loscalzo, J.; Zimmerman, G.A.; McEver, R.P.; Pober, J.S.; Wick, T.M.; Konkle, B.A.; Schwartz, B.S.; Barnathan, E.S.; McCrae, K.R.; Hug, B.A.; Schmidt, A.M.; Stern, D.M. (1998):

Endothelial cells in physiology and in the pathophysiology of vascular disorders.

Blood, 91: 3527-3561.

- Clarke, G.; Higgins, T. (2000):**
Laboratory investigation of hemoglobinopathies and thalassemias.
Clinical Chemistry, 46: 1284-1290.
- Cox, T.; Bottomley, S.; Wiley, J.; Dowden, M.; Matthews, C.; May, B. (1994):**
X-linked pyridoxine-responsive sideroblastic anaemia due to a Thr³⁸⁸-to-Ser substitution in erythroid δ -aminolevulinate synthase.
N. Engl. J. Med., 330: 675-679.
- Cynober, T.; Mohandas, N.; Tchernia, G. (1996):**
Red cell abnormalities in hereditary spherocytosis: relevance to diagnosis and understanding of the variable expression of clinical severity.
J. Lab. Clin. Med., 128: 259-269.
- David, G.W. (1996):**
Diagnosis and management of chronic renal failure. In Cecil next book of medicine, 20th ed. Eds, Claude Bennet and Fred Plum.
- Davis, I.; Bundsman, T.E. and Grignon, P.C. (1998):**
Pediatric renal Trans.: indications and special considerations
Ped. Transplant., 2: 117-129.
- Delwiche, F.; Segal, G.; Eschbach, J.; Adamson, J. (1986):**
Haematopoietic inhibitors in chronic renal failure: lack of in vitro specificity.
Kidney Int., 29(3): 641-648.
- Eckardt, K.; Casadevall, N. (2003):**
Pure red-cell aplasia due to anti-erythropoietin antibodies.
Nephrol. Dial. Transplant., 18: 865-869.
- Eknoyan, G. (2001):**
The importance of early treatment of anaemia of chronic kidney disease.
Nephrol. Dial. Transplant., 16(5): 45-49.
- Eldor, A.; Rachmilewitz, E. (2002):**
The hypercoagulable state in thalassemia.

Blood, 99(10): 36-43.

Erslev, A.; Besarab, A. (1997):

Erythropoietin in the pathogenesis and treatment of anaemia of chronic renal failure.
Kidney Int., 51: 622-630.

Eschbach, J.; Adamson, T.; Egrie, J. (1988):

Recombinant EPO implications for nephrology.
American Journal of Kidney Disease, 11: 203-209.

Eschbach, J.; Haley, N.; Egrie, J. (1990):

The anaemia of renal failure.
Journal of Nephrology, 78: 24-37.

Eschbach, J. (1994):

Erythropoietin: the promise and the facts.
Kidney Int., 45(44): S70-76.

Eschbach, J.; Deoreo, P.; Adamson, J. (1997):

NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure.
Am. J. Kidney Dis., 30: S192-240.

Ewenstein, B.M. (1997):

Vascular biology of von Willebrand factor; in Born GVR, Schwartz CJ (eds): Vascular Endothelium: Physiology, Pathology, and Therapeutic Opportunities. Stuttgart, Schattauer, pp 107-123.

Fabry, M.; Fine, E.; Rajanayagam, V.; Factor, S.; Gore, J.; Sylla, M.; Nagel, R. (1992):

Demonstration of endothelial adhesion of sickle cells in vivo: A distinct role for deformable sickle cell discocytes.
Blood, 79: 1602-1611.

Fanti, P.; Sawaya, B.P.; Custer, L.J.; Franke, A.A. (1999):

Serum levels and metabolic clearance of the isoflavones genistein and daidzein in hemodialysis patients.
J Am Soc Nephrol.; 10:864-871.

Fennel, E.B.; Fennel, R.S. and Mings, E. (1986):

The effects of various modes of therapy for ESRD on cognitive performance in ped. Population.
Int. J. Ped. Nephrol., 2: 107-12.

Ferreira, J.; Feliu, E.; Rozman, C. (1989):

Morphologic and morphometric light and electron microscopic studies of the spleen in patients with hereditary spherocytosis and autoimmune haemolytic anaemia.
Br. J. Haematol., 72: 246-253.

Finch, S. (2000):

Bone marrow failure syndrome.
N. Engl. J. Med., 343: 350.

Fleck, A.; Myers, M.A. (1985):

Diagnostic and prognostic significance of the acute-phase proteins; in Gordon AH, Koj A (eds): The Acute-Phase Response to Injury and Infection. Amsterdam, Elsevier, pp 249-271.

Foreman, J.W. and Chan, J.C.M. (1988):

Chronic renal failure in infants and children.
J. Pediatrics, 113: 793-800.

Franz Schafeer and Otto Mehts (1998):

Endocrine and growth disturbance in children with CRF, from Ped. Neph. Text Book, 4th ed., 79: 1197-1000.

Gabay, C.; Kushner, I. (1999):

Acute-phase proteins and other systemic responses to inflammation.
N. Engl. J. Med., 340: 448-454.

Galle, J.; Heermeier, K.; Wanner, C. (1999):

Atherogenic lipoproteins, oxidative stress, and cell deaths.
Kidney, Int., 71(Suppl): 62-65.

Goicoechea, M.; Martin, J.; de Sequera, P.; Quiroga, J.A.; Ortiz, A.; Carreno, V.; Caramelo, C. (1998):

Role of cytokines in the response to erythropoietin in hemodialysis patients.
Kidney Int., 54: 1337-1343.

- Goodnough, L.; Monk, T. and Andriole, G. (1997):**
Erythropoietin therapy.
N. Eng. J., 336: 933-938.
- Gris, J.C.; Branger, B.; Vecina, F.; al Sabadani, B.; Fourcade, J.; Schved, J.F. (1994):**
Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients.
Kidney Int., 446: 807-813.
- Guest, S.; Levitt, L. (2003):**
Pure Red-Cell Aplasia Secondary to Anti-erythropoietin Antibodies.
N. Engl. J. Med., 349: 2572-2573.
- Gunnell, J.; Yeun, J.Y.; Depner, T.A.; Kaysen, G.A. (1999):**
Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients.
Am. J. Kidney Dis., 33: 63-72.
- Harman, W.E. and Jabs, K.L. (1999):**
Heamodialysis: In Pediatric nephrology Eds: Martin T, Ellis D, William E. 4th ed. Lippincott, Williams and Wilkins, Baltimore, Maryland, P: 1267-87.
- Hassoun, H.; Palek, J. (1996):**
Hereditary spherocytosis: a review of the clinical and molecular aspects of the disease.
Blood Rev., 10: 129-147.
- Hassoun, H.; Vassiliadis, J.; Murray, J. (1997):**
Characterization of the underlying molecular defect in hereditary spherocytosis associated with spectrin deficiency.
Blood, 30: 398-406.
- Heeschen, C.; Aicher, A.; Lehmann, R.; Fichtlscherer, S.; Vasa, M.; Urbich, C.; Mildner-Rihm, C.; Martin, H.; Zeiher, A.; Dimmeler, S. (2003):**
Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization.
Blood, 102(4): 1340-1346.

Hokken, A.C.; Van Zeal and Van Bergen (1999):

Final hight and its prediction factor after renal transplantation in childhood.
Pediatrics, 36: 323-28.

Horl, W. (1996):

How to diagnose and correct iron deficiency during rHuEPO therapy.
Nephrol. Dial. Transplant., 11: 246-250.

Horl, W. (1999):

Is there a role for adjuvant therapy in patient being treated with epoetin?
Nephrol. Dial. Transplant., 14(2): 50-60.

Ifudo, O.; Feldman, J.; Friedman, E. (1996):

The intensity of haemodialysis and the response to erythropoietin in patients with end-stage renal disease.
N. Engl. J. Med., 334: 420-425.

Irish, A. (1997):

Plasminogen activator inhibitor-1 activity in chronic renal disease and dialysis.
Metabolism., 46: 35-40.

Irish, A. (1998):

Cardiovascular disease, fibrinogen and the acute phase response associations with lipids and blood pressure in patients with chronic renal disease.
Atherosclerosis, 137: 133-139.

Iseki, K.; Yamazato, M.; Tozawa, M.; Takishita, S. (2002):

Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients.
Kidney Int; 61:1887-1893.

Jeren-Strujic, B.; Crnjakovic, J.; Raos, V.; Gudel, J. (2001):

Comparison and efficacy of alfa and beta erythropoietin therapy of anaemia in patients.
Neph. Dial. Transplant., 16(6): A132.

- Jsky Gordon and Rose de Burgn (1998):**
Diagnostic imaging of renal disease, from text book of Ped. Meph., 4th ed., 22: P: 377-391.
- Kalantar-Zadeh, K.; Kopple, J. (2003):**
Inflammation in renal failure. *UpToDate*, eds Rose BD and Post TW. UpToDate, Boston.
- Kario, K.; Matsuo, T.; Kobayashi, H.; Matsuo, M.; Asada, R.; Koide, M. (1995):**
High lipoprotein (a) levels in chronic hemodialysis patients are closely related to the acute phase reaction. *Thromb. Haemost.*, 74: 1020-1024.
- Kellehere, B.; Wall, C.; O'Broin, S. (2001):**
Haemoglobin, not haematocrit, should be the preferred parameter for the evaluation of anaemia in renal patients. *Nephrol. Dial. Transplant.*, 16: 1085-1087.
- Kher, K.K. (1992):**
Conservative management of CRF. In: *Clinical Ped. Nephrology*: Kher, K.K. and Makker, SP.; McGraw-Hill Inc., Health Professions. Division, New York, 1st edition, PP. 543-557.
- Kimmel, P.L.; Phillips, T.M.; Simmens, S.J. et al. (1998):**
Immunologic function and survival in hemodialysis patients. *Kidney Int.*;54:236-244.
- Kirby, E.P.; Mills, D.C.B. (1987):**
Methods for studying the von Willebrand factor-platelet interactions; in Colman RW, Smith JB (eds): *Methods for Studying Platelets and Megakaryocytes: Modern Methods in Pharmacology*. New York, Liss, pp 65-89.
- Klahr, S. (1996):**
Anaemia, Dialysis, and Dollars. *N. Engl. J. Med.*, 334: 461-463.
- Kobayashi, H.; Ono, T.; Yamamoto, N. (1993):**
Removal of high molecular weight substances with large pore size membrane (BK-F). *Kidney Dial.*, 34(1): 154-157.

Koo, W. and Kaplan, L.A. (1988):

Aluminum and bone disorders with specific reference on aluminum contamination of infants nuritents.
J.A.M. Nut., 7(3): 199-214.

Koury, M.; Park, D.; Martincic, D.; Horne, D.; Kravtsov, V.; Whitlock, J.; Aguinaga, M.; Kopsombut, P. (1997):

Folate deficiency delays the onset but increases the incidence of leukaemia in friend virus-infected mice.
Blood, 90(10): 4054-4061.

Kronenberg, F.; Trenkwalder, E.; Kronenberg, M.F.; Konig, P.; Utermann, G.; Dieplinger, H. (1998):

Influence of hematocrit on the measurement of lipoproteins demonstrated by he example of lipoprotein(a).
Kidney Int., 54: 1385-1389.

Kushner, I. (2003):

Acute phase proteins. In *UpToDate*, eds Rose B and Wellesley MA. UpToDate, Boston, MA.

Lacombe, C. (1996):

Resistance to Erythropoietin.
N. Engl. J. Med., 334: 660-662.

Llach, F. and Bover, J. (2000):

Renal osteodystrophy. In: *The kidney diseases*, Eds: Brenner BM, 6th ed., Philadelphia, P: 2103-66.

Locatelli, F.; Andrulli, S.; Pecchini, F. (2000):

Effect of high-flux dialysis on the anaemia of haemodialysis patients.
Nephrol. Dial. Transplant., 15: 1399-1409.

Locatelli, F.; Del Vecchio, L.; Andrulli, S. (2001a):

Dialysis: its role in optimizing recombinant erythropoietin.
Nephrol. Dial. Transplant., 16(7): 29-35.

Locatelli, F.; Vecchio, L.; Andrulli, S. (2001b):

The modality of dialysis treatment: does it influence the response to erythropoietin treatment?
Nephrol. Dial. Transplant., 16: 1971-1974.

- Locatelli, F.; Aljama, P.; Barany, P.; Canaud, B.; Carrera, B.; Eckardt, K.; Macdougall, L.; Macleod, A.; Horl, W.; Wiecek, A.; Cameron, S. (2004):**
Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here?
Nephrol. Dial. Transplant., 19: 288-293.
- Losekann, A.; Urena, P.; Khiraoui, F. (1990):**
Aluminium intoxication in the rat induces partial resistance to the effect of recombinant human erythropoietin.
Nephrol. Dial. Transplant., 5: 258-263.
- Lowbeer, C.; Stenvinkel, P.; Pecoits-Filho, R. et al. (2003):**
Elevated cardiac troponin T in predialysis patients is associated with inflammation and predicts mortality.
J. Intern. Med., 253:153-160.
- MacDougall, I.; Roberts, D.; Coles, G.; Williams, J. (1991):**
Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin. Pharmacokinet., 20(2): 99-113.
- MacDougall, I.C. (1998a):**
Treatment of renal anaemia with rhEPO.
Curr. Opin. Nephron. Hypertens., 1: 210-219.
- MacDougall, I.C. (1998b):**
Meeting the challenges of a new millennium: optimizing the use of recombinant human erythropoietin.
Nephrol. Dial. Transplant., 13(2): 23-27.
- MacDougall, I.C. (1999):**
Strategies for iron supplementation: oral versus intravenous.
Kidney Int., 69(1): S61-S66.
- MacDougall, I.C. (2001):**
Individualizing target haemoglobin concentrations-tailoring treatment for renal anaemia.
Nephrol. Dial. Transplant., 16(7): 9-14.
- MacDougall, I.C. (2004):**

Pure red cell aplasia with antierythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another.

Current Medical Research and Opinion, 20(1): 83-86.

Madore, F.; Lowire, E.G.; Brugnara, C.; Lew, N.L.; Lazarus, J.M.; Bridges, K.; Owen, W.F. (1997):

Anemia in hemodialysis patients: Variables affecting this outcome predictor.

J. Am. Soc. Nephrol., 8: 1921-1927.

Major, A.; Mathez-Loic, F.; Rohling, R.; Gautschi, K.; Brugnara, C. (1997):

The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin.

Br. J. Haematol., 98: 292-294.

Mann, J.F.; Gerstein, H.C.; Pogue, J.; Bosch, J.; Yusuf, S. (2001):

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial.

Ann. Intern. Med.; 134:629-636.

Markowitz, G.; Kahn, G.; Feingold, R.; Coco, M.; Lyn, R. (1997):

An evaluation of the effectiveness of oral iron therapy in haemodialysis patients receiving recombinant human erythropoietin.

Clin. Nephrol., 148: 34-40.

Marti, H.; Wenger, R.; Rivas, L.; Straumann, U.; Digicaylioglu, M.; Henn, V.; Yonekawa, Y.; Bauer, C.; Gassmann, M. (2000):

Erythropoietin gene expression in human, monkey and murine brain.

Eur. J. Neurosci., 8: 666-676.

Massoud, W.; Abol Fottouh, N. (1999):

The effect of parental iron in the treatment of anaemia of chronic renal failure without the use of recombinant erythropoietin. 18th annual national congress of the Egyptian society of nephrology, 59.

Mast, A.; Blinder, M.; Lu, Q.; Flax, S.; Dietzen, D. (2002):

Clinical utility of the reticulocyte haemoglobin content in the diagnosis of iron deficiency.
Blood, 99(4): 1489-1491.

Meunier, B.; Gauthier, F.; Archambaud, F.; Cynober, T.; Mielot, F.; Dommergues, J.; Warszawski, J.; Mohandas, N.; Tchernia, G. (2001):
Long-term evaluation of the beneficial effect of subtotal splenectomy for management of hereditary spherocytosis.
Blood, 97(2): 399-403.

Miles, L.A.; Fless, G.; Levin, E.G.; Scanu, A.M.; Plow, E.F. (1989):
A potential basis for thrombotic risks associated with lipoprotein(a).
Nature, 339: 301-303.

Moreno, F.; Guajardo, D.; Gomez, J.; Jofre, R.; Valderrabano, F. (2000):
Increasing the Hematocrit Has a Beneficial Effect on Quality of Life and Is Safe in Selected Hemodialysis Patients.
J. Am. Soc. Nephrol., 11: 335-342.

National Kidney Foundation- Dialysis Outcome Quality Initiative (2003):
NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure.
Am. J. Kidney Dis., 30 (Suppl. 3): 192-240.

Newman Dorland, W.; Anderson, D. (1999):
Dorland's Illustrated Medical Dictionary, Saunders, Philadelphia, PA 2000. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med.; 340:448-454.

Noguchi, G.; Rodgers, G.; Schechter, A. (1989):
Intracellular polymerization: disease severity and therapeutic predictions.
Ann. N. Y. Acad. Sci., 565: 75-82.

Norwood, K.; Slatapolsky, E. and Weerts (1998):
Long term effects of Ca carbonate on mineral metabolism.
Kid. Int., 36: 897.

- Obrador, G.; Pereira, B. (2002):**
Systemic complications of chronic kidney disease.
Journal of Postgraduate Medicine, 111(2): 115-122.
- Oski Frank, A.; Catherine, D.; DeAngelis, Ralph, D.; Feigin, Jlia, A.;
McMillan, Joseph, B. Warshaw (1994):**
Principles and practice of pediatrics chronic renal failure 2nd
edition, P 1772-1780.
- Owen, W.F.; Lowrie, E.G. (1998):**
C-Reactive protein as an outcome predictor for maintenance
hemodialysis patients.
Kidney Int.; 54:627-636.
- Peces, R.; de La Torre, M.; Alcazar, R.; Urra, J. (1996):**
Antibodies against recombinant human erythropoietin in a
patient with erythropoietin-resistant anemia.
N. Engl. J. Med., 335: 523-524.
- Pecoits-Filho, R.; Heimbürger, O.; Barany, P. et al. (2003):**
Associations between circulating inflammatory markers and
residual renal function in CRF patients.
Am. J. Kidney Dis.; 41:1212-1218.
- Pecoits-Filho, R.; Lindholm, B.; Stenvinkel, P. (2003):**
End-stage renal disease: A state of chronic inflammation and
hyperleptinemia.
Eur J Clin Invest; 33:527-528.
- Pereira, B.J.G.; Cheung, A.K. (2000):**
Complications of bioincompatibility of hemodialysis
membranes; in Lameire N, Mehta RL (eds): Complications
of Dialysis. New York, Marcel Dekker, pp 41-69.
- Peterson, J.C. (1995):**
Chronic renal failure. In: Pediatric Nephrology, 3rd edition,
Ticher CC and Wilcox CS. Eds. Mass Publishing Co.,
William and Wilkins, London, P: 443.
- Prabhakar, S.; Muhlfelder, T. (1997):**
Antibodies to recombinant human erythropoietin causing
pure red cell aplasia.
Clin. Nephrol., 47: 331-335.

- Prasad, A.S. (1963):**
Zinc metabolism in patients with Fe deficiency anemia,
HSM, Dwarfism.
Journal of Clin. Med., 61: 537.
- Purkerson, M.I. and Cole, B.R. (1990):**
CRF in Ped., textbook of fluid and electrolyte; Eds; William
and Wilkins, P: 242.
- Qureshi, A.R.; Alvestrand, A.; Divino-Filho, J.C. et al. (2002):**
Inflammation, malnutrition, and cardiac disease as predictors
of mortality in hemodialysis patients.
J. Am. Soc. Nephrol.; 13:S28-S36.
- Rao, D.; Shih, M.; Mohini, R. (1993):**
Effect of serum parathyroid hormone and bone marrow
fibrosis on the response to erythropoietin in uremia.
N. Engl. J. Med., 328: 171-175.
- Rees, L.; Ridgen, S.P. and Word, G.M. (1989):**
CRF and growth.
Arch. Dis. Child., 64: 573-77.
- Revised European Best Practice Guidelines for Management of
Anaemia in Patients with Chronic Renal Failure (2004):**
Neph. Dial. Transplant., 19(2).
- Robb, J.; Khoschorur, G.; Tiran, A.; Horin, A.; Holzer, H.;
Winkelhofer-Roob, B. (2000):**
Vitamin E Attenuates oxidative stress induced by
intravenous iron in patients on hemodialysis.
J. Am. Soc. Nephrol., 11: 539-549.
- Sasaki, H.; Bothner, B.; Dell, A.; Fukuda, M. (1987):**
Carbohydrate structure of erythropoietin expressed in
Chinese hamster ovary cells by a human erythropoietin
cDNA.
J. Biol. Chem., 262: 12059-12076.

- Schaefer, R.M.; Paczek, L.; Berthold, G.; Gilge, U.; Heidland, A. (1992):**
Improved immunoglobulin production in dialysis patients treated with recombinant erythropoietin.
Int. J. Artif. Organs., 15: 204-208.
- Schellekens, H. (2003):**
Immunogenicity of therapeutic proteins.
Nephrol. Dial. Transplant., 18: 1257-1259.
- Schoefer, F.; Weicek, A. and Ritz, E. (1998):**
Endocrine disorders. In: Oxford text book of Clin. Neph., 2nd ed., Eds, Alexander M, J. Stewants, Jean Pearre; Oxford New York, Tokyo, Oxford University, P: 1854-65.
- Segarra, A.; Chacon, P.; Martinez-Eyarre, C.; Argelaguer, X.; Vila, J.; Ruiz, P.; Fort, J.; Bartolome, J.; Camps, J.; Moliner, F.; Pelegri, A.; Marco, F.; Olmos, A.; Piera, L. (2001):**
Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: Biochemical correlations and role as independent predictors of coronary artery stenosis.
J. Am. Soc. Nephrol., 12: 1255-1261.
- Shlipak, M.G.; Chertow, G.C.; Massie, B.M. (2003):**
Beware the rising creatinine level.
J. Card. Fail; 9:26-28.
- Shorecki, K.; Green, J.; Barry, B. (2001):**
Chronic renal failure. In: Braunwald E, Fauci AS, Isselbacher K, Kasper DL, Hauser SL, Longo DL, Jameson JL, ed. 15th edition. McGrow Hill, New York, 1551-1561.
- Sipsas, N.; Kokori, S.; Ioannidis, J.; Kyriaki, D.; Tzioufas, A.; Kordosis, T. (1999):**
Circulating autoantibodies to erythropoietin are associated with human immunodeficiency virus type-1 related anaemia.
The Journal of Infections Diseases, 180: 1207-1211.
- Sitter, T.; Bergner, A.; Schiff, H. (2000):**
Dialysis related cytokine induction and response to recombinant erythropoietin in haemodialysis patients.
Nephrol. Dial. Transplant., 15: 1207-1211.

- Stenvinkel, P.; Heimbürger, O.; Tuck, C.H.; Berglund, L. (1998):**
Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure.
Kidney Int., 53: 1336-1342.
- Stenvinkel, P. (2001):**
The role of inflammation in the anaemia of end-stage renal disease.
Nephrol. Dial. Transplant., 16(7): 36-40.
- Stenvinkel, P.; Barany, P.; Heimbürger, O.; Pecoits-Filho, R.; Lindholm, B. (2002):**
Mortality, malnutrition, and atherosclerosis in ESRD: What is the role of interleukin-6?
Kidney Int.; 80:S103-S108.
- Steven, J. and Michelle Baum (1998):**
Physiology and management of CRF in pediatric age group, from pediatric nephrology, 72: 1156-58.
- Streetz, K.L.; Wustefeld, T.; Klein, C.; Manns, M.P.; Trautwein, C. (2001):**
Mediators of inflammation and acute phase response in the liver.
Cell Mol Biol (Noisy-le-grand) 47:661-673.
- Suffredini, A.F.; Fantuzzi, G.; Badolato, R.; Oppenheim, J.J.; O'Grady, N.P. (1999):**
New insights into the biology of the acute phase response.
J. Clin. Immunol.; 19:203-214.
- Summerfield, G.; Gyde, O.; Forber, A.; Goldsmith, H.; Belingham, A. (1983):**
Haemoglobin concentration and serum erythropoietin in renal dialysis and transplant patients.
Scand. J. Haematol., 30(4): 389-400.
- Tatli, M.M.; Vural, H.; Koc, A.; Kosecik, M.; Atas, A. (2000):**
Altered anti-oxidant status and increased lipid peroxidation in marasmic children.
Pediatr. Int.; 42:289-292.

Thomas, C. and Thomas, L. (2002):

Biochemical markers and Haematologic indices in the diagnosis of functional iron deficiency.
Clinical Chemistry, 48: 1066-1076.

Tonshoff and Fine (1995):

Growth and growth hormone treatment in children with chronic renal insufficiency. In: Clinical dialysis, 3rd ed., Allen R, Nissenson, Richard, N. Fine, P. 567-79.

Tse, W.; Lux, S. (1999):

Red blood cell membrane disorders.
Br. J. Haematol., 104: 2-13.

Turner, C.; Copston, J. and Mack, R.H. (1998):

Bone turnover and 1.25 dihydroxy cholecalciferol with phosphate binders.
Kid. Int., 3: 189-59.

Tzioufas, A.; Kokori, S.; Petrovas, C.; Moutsopoulos, H. (1997):

Autoantibodies to human recombinant erythropoietin in patients with systemic lupus erythematosus.
Arthritis and Rheumatism, 40(12): 2212-2216.

Valderrabano, F.; Horl, W.; MacDougall, L.; Rossert, J.; Rutkowski, B.; Wauters, J. (2003):

PRE-dialysis survey on anaemia management.
Nephrol. Dial. Transplant., 18: 89-100.

Valtuille, R.; Ferro, H.; Gonzalez, E.; Lef, L.; Mac Gaul, G.; Alvarez, P.; Carlomagno, H.; Fernandez, J. (2004):

Prevalence of anti-erythropoietin antibodies in haemodialysis patients. Proceedings of the 41st Congress of the European Dialysis and Transplantation Association Lisbon, Portugal. May, 15-18, pp. 115.

Van Hove, L.; Schisano, T.; Brace, L. (2000):

Anaemia diagnosis, classification, and monitoring using cell-Dyne technology reviewed for the New Millennium.
Laboratory Haematology, 6: 93-108.

Van Wyck, D. (2000):

Management of early renal anaemia: diagnostic work-up, iron therapy, epoetin therapy.
Nephrol. Dial. Transplant., 15(3): 36-39.

Vanholder, R. and Smet, R. (1999):

Pathophysiologic effects of uremic retention solutes.
J. Am. Soc. Nephrol., 10: 1815-1823.

Vaziri, N.; Zhou, X.; Naqvi, F.; Smith, J.; Oveisi, F.; Wang, Z.; Purdy, R. (1996):

Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure.
Am. J. Physiol., 271: E113-22.

Villaverde, M.; Perez-Garcia, R.; Verde, E. (2001):

La polisulfona de alta permeabilidad mejora la respuesta de la anemia a la eritropoyetina en hemodialisi. Nefrologia 1999; 19:161-167. Quoted from Locatelli F, del Vecchio L, Andrulli S. Dialysis: its role in optimizing recombinant erythropoietin. Nephrol. Dial. Transplant., 16(7): 29-35.

Walkers, K. (1997):

General management of end stage-renal disease (Description and management of non-renal complications of end-stage renal disease, this includes cardiovascular disease, anemia, diet, hypertension, hyper lipedemia and hyper parathyroidism).

Warnock, P.G. (1996a):

CRF. In: Cecil textbook of medicine, 20th ed., Bennetle JC and Alen F, Eds, WB Saunders Co., Philadelphia, P: 586.

Warnock, P.G. (1996b):

Uremic acidosis. A review of the renal responses to chronic acidosis, the importance of chronic acidosis in the development of renal osteodystrophy. Kid. Int., 34: 278.

Wassner, S.J. (1982):

The role of nutrition in the case of children with CRF, Ped. Clinics of North America; 9: 973.

Wassner, S.J. and Baum, M. (1999):

Physiology and management of CRF, from Ped. Neph., Eds: Barrat TM, Avenier ED, Harman WE, 4th ed., Lippincott William and Wilkins, P. 1155-82.

Weber, G.; Gross, J.; Lromminga, A.; Loew,, H.; Eckardt, K. (2002):

Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins.
J. Am. Soc. Nephrol., 13: 2381-2383.

Weiss, L.; Clyne, N.; Fihlho, J. (2000):

The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled multicentre trial.
Nephrol. Dial. Transplant., (15): 2014-2019.

Whitehead, V.M. (1979):

Renal dialysis treatment and haematological system. In: Heamatological problems in renal disease. Ed; Jepson M, Addison Wesleg publishing Co., Califronia USA, P: 145.

William, E. Mitch (1998):

The heart and kidney disease. From Hursts text book of Cardiology, 94: 2410-21.

Wilsoncroft, P.S.; Lofts, F.J.; Griffiths, R.J.; Moore, P.K. (1985):

The effect of 6-oxoPGE1 on human platelet aggregation in whole blood in vitro.
J. Pharm. Pharmacol., 371: 139-141.

Wingard, R.; Parker, R.; Ismail, N.; Hakim, R. (1995):

Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin.
Am. J. Kidney Dis., 25: 433-439.

Yeun, J.Y.; Levine, R.A.; Mantadilok, V.; Kaysen, G.A. (2000):

C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients.
Am. J. Kidney Dis., 35:469-476.

Young, E.; Wood, J.; Segieda, G.; Held, P.; Port, F.; Bloembergen, W. (1997):

Predictors of target haematocrite among erythropoietin treated HD patients.

J. Am. Soc. Nephrol., 8: 259A.

Young, N.; Maciejewski, J. (1997):

The pathophysiology of acquired aplastic anaemia.

N. Engl. J. Med., 336: 1365-1372.

Zimmerman, J.; Herrlinger, S.; Pruy, A.; Metzger, T.; Wanner, C. (1999):

Inflammation enhances cardiovascular risk and mortality in hemodialysis patients.

Kidney Int., 55: 648-658.